Skystar Bio-Pharma revises 2012 revenue view to $38M from $33M prior Fiscal 2012 top line revenue guidance reflects inactivity of the veterinary medications facility due to timing of its GMP re-certification process.
News For SKBI From The Last 14 Days
Check below for free stories on SKBI the last two weeks.
